Cardio Diagnostics Holdings, Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and an increase in net losses compared to the same period in the previous year. The company generated revenue of $2,855 for the three months ended September 30, 2025, a decrease of approximately 57% from $6,580 in the same quarter of 2024. For the nine months ended September 30, 2025, revenue totaled $11,270, down from $30,378 in the prior year. The decline in revenue is attributed to the conclusion of a testing initiative with Family Medicine Specialists, which has impacted the onboarding of new provider organizations.
The company's net loss for the third quarter of 2025 was $1,714,536, compared to a loss of $1,412,566 in the same quarter of 2024, marking an increase of 21%. For the nine-month period, the net loss decreased to $5,032,799 from $6,864,145 in the previous year, primarily due to reduced general and administrative expenses, particularly in stock compensation. Total operating expenses for the third quarter rose to $1,714,452, up from $1,415,547 in the prior year, driven by increased personnel and professional fees.
In terms of operational developments, Cardio Diagnostics has focused on expanding its product offerings and market reach. The company launched its second product, PrecisionCHD™, in March 2023, and has continued to develop its sales pipeline, targeting larger provider organizations and employers. The company has also made strides in geographic expansion, partnering with the YMCA of East Tennessee to offer testing services. As of September 30, 2025, Cardio Diagnostics had 1,766,607 shares of common stock outstanding, reflecting a reverse stock split that took effect in May 2025.
Looking ahead, Cardio Diagnostics aims to enhance its product portfolio by developing additional clinical tests for conditions such as stroke and diabetes, while also expanding its laboratory services. The company plans to leverage its CPT PLA codes to improve reimbursement efforts and increase product adoption across key channels. However, the management acknowledges that sales and partnership cycles may remain lengthy due to current economic uncertainties. The company’s cash position at the end of the third quarter was $6,355,218, down from $7,827,487 at the end of 2024, indicating ongoing liquidity challenges as it seeks to fund operations and growth initiatives.
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops AI-driven epigenetic and genetic blood tests for cardiovascular disease risk assessment and early detection. Its flagship products, Epi+Gen CHD and PrecisionCHD, provide personalized insights to clinicians, payors, and health systems. The company aims to shift cardiovascular care from reactive to proactive, leveraging proprietary technology, strategic partnerships, and a broad market opportunity to improve prevention, diagnosis, and management of heart disease.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.